- Home
- VCYT
VCYT
Veracyte Inc.
as 11-07-2025 3:52pm EST
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 2.9B | IPO Year: | 2013 |
| Target Price: | $42.40 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $22.61 - $47.32 | Next Earning Date: | 11-04-2025 |
| Revenue: | $495,141,000 | Revenue Growth: | 16.41% |
| Revenue Growth (this year): | 14.52% | Revenue Growth (next year): | 9.90% |
Stock Insider Trading Activity of Veracyte Inc. (VCYT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chambers Rebecca | VCYT | Chief Financial Officer | Nov 5 '25 | Sell | $41.00 | 7,000 | $287,000.00 | 126,158 | |
| McGuire Annie | VCYT | SVP, General Counsel | Nov 5 '25 | Sell | $40.00 | 6,466 | $258,640.00 | 82,973 | |
| JONES EVAN/ FA | VCYT | Director | Nov 5 '25 | Sell | $44.29 | 43,196 | $1,946,287.73 | 30,468 | |
| EASTHAM KARIN | VCYT | Director | Nov 5 '25 | Sell | $40.02 | 9,674 | $387,191.21 | 13,554 | |
| Febbo Phillip G. | VCYT | Chief Scientific & Med Officer | Oct 6 '25 | Sell | $36.02 | 8,349 | $300,709.27 | 92,441 | |
| McGuire Annie | VCYT | SVP, General Counsel | Oct 1 '25 | Sell | $35.00 | 2,160 | $75,607.56 | 82,973 | |
| Leite John | VCYT | Chief Commercial Officer-CLIA | Oct 1 '25 | Sell | $35.00 | 2,539 | $88,865.00 | 89,099 | |
| EPSTEIN ROBERT S | VCYT | Director | Oct 1 '25 | Sell | $35.08 | 21,473 | $753,204.13 | 62,446 | |
| McGuire Annie | VCYT | SVP, General Counsel | Sep 19 '25 | Sell | $33.69 | 2,283 | $76,919.52 | 82,973 | |
| Stapley Marc | VCYT | Chief Executive Officer | Sep 4 '25 | Sell | $30.41 | 7,667 | $233,132.77 | 334,185 |
Latest Veracyte Inc. News
VCYT Breaking Stock News: Dive into VCYT Ticker-Specific Updates for Smart Investing
MT Newswires
19 days ago
Canaccord Genuity Initiates Coverage on Veracyte With Hold Rating, $40 Price Target
Simply Wall St.
21 days ago
How the Narrative Around Veracyte Is Evolving With Recent Analyst Updates and Pipeline Progress
Simply Wall St.
21 days ago
Is Veracyte's (VCYT) Margin Growth and New Platform Shaping Its Long-Term Diagnostic Edge?
MT Newswires
a month ago
Veracyte Insider Sold Shares Worth $753,204, According to a Recent SEC Filing
Simply Wall St.
2 months ago
How Investors May Respond To Veracyte (VCYT) Earnings Upgrades and Spotlight as a Momentum Stock
Zacks
3 months ago
Here's Why Veracyte (VCYT) is a Strong Momentum Stock
Simply Wall St.
5 months ago
Veracyte (NASDAQ:VCYT) shareholders have earned a 19% return over the last year
Zacks
5 months ago
Veracyte (VCYT) Down 13.6% Since Last Earnings Report: Can It Rebound?
Compare VCYT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VCYT Veracyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.